Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › regorafenib

regorafenib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of regorafenib

31 trials tracked of regorafenib: 5 in phase 3 or 4 and 4 with published results. The most-cited published study has 559 citations.

31Trials tracked
5Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 5 Phase 2 22 Phase 1 3 Other / NA 1
  1. Phase 3 A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) Completed · 559 cited
  2. Phase 3 (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST Completed · 116 cited
  3. Phase 3 Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) Completed · 76 cited
  4. Phase 3 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) Completed · 4 cited
  5. Phase 3 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study Completed
  6. Phase 2 A Study of Regorafenib in Advanced Pancreatic Cancer Patients Completed
Show 25 more trials
  1. Phase 2 Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed
  2. Phase 2 Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) Completed
  3. Phase 2 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed
  4. Phase 2 Phase II Study of Perindopril and Regorafenib in mCRC Completed
  5. Phase 2 SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Completed
  6. Phase 2 Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer Completed
  7. Phase 2 An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread Completed
  8. Phase 2 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed
  9. Phase 2 A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer Completed
  10. Phase 2 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Completed
  11. Phase 2 A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy Completed
  12. Phase 2 Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer Completed
  13. Phase 2 Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer Completed
  14. Phase 2 Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases Completed
  15. Phase 2 An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Completed
  16. Phase 2 Single Agent Regorafenib in Refractory Advanced Biliary Cancers Completed
  17. Phase 2 Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma Completed
  18. Phase 2 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Completed
  19. Phase 2 FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer Completed
  20. Phase 2 Regorafenib in Metastatic Colorectal Cancer Completed
  21. Phase 2 Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Completed
  22. Phase 1 Regorafenib and Nivolumab Simultaneous Combination Therapy Completed
  23. Phase 1 Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST Completed
  24. Phase 1 To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer Completed
  25. N/A [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib Completed

Showing the 31 most-cited and recently-updated of 31 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Regorafenib plus nivolumab in second-line hepatocellular carcinoma showed safety and survival signals in a Phase IIa trial
Gastroenterology Phase II
Regorafenib plus nivolumab in second-line hepatocellular carcinoma showed safety and survival signals in a Phase IIa trial Some Liver Cancer Patients Are Surviving Far Longer on a New Drug Combination
This Phase IIa trial evaluated regorafenib plus nivolumab as an add-on therapy in patients with hepatocellular carcinoma who had progressed …
A combination of regorafenib and nivolumab showed unexpectedly long survival in people with advanced liver cancer who had already exhausted …
Apr 14, 2026
Phase I trial of regorafenib plus ipilimumab and nivolumab shows 27.6% response in MSS colorectal cancer
Gastroenterology Phase I
Phase I trial of regorafenib plus ipilimumab and nivolumab shows 27.6% response in MSS colorectal cancer Who Really Responds to a Stubborn Colon Cancer Combo?
A phase I trial in 29 patients with microsatellite-stable metastatic colorectal cancer tested the combination of regorafenib, ipilimumab, an…
A three-drug combo helped some patients with stubborn colon cancer, and immune markers now predict who will benefit most.
Apr 14, 2026